Specifically, loss-of-function PTEN deletions and activating mutations of PI3KCA, two of the most frequent genetic alterations in BC, cause increased activity of the PI3K/Akt pathway and can contribute to trastuzumab resistance[118]. The gene discussed is AKT1; the disease is breast cancer.